335 related articles for article (PubMed ID: 18292232)
1. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway.
Zarnegar B; Yamazaki S; He JQ; Cheng G
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3503-8. PubMed ID: 18292232
[TBL] [Abstract][Full Text] [Related]
2. Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway.
He JQ; Saha SK; Kang JR; Zarnegar B; Cheng G
J Biol Chem; 2007 Feb; 282(6):3688-94. PubMed ID: 17158868
[TBL] [Abstract][Full Text] [Related]
3. TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway.
Al-Sadi R; Guo S; Ye D; Rawat M; Ma TY
Am J Pathol; 2016 May; 186(5):1151-65. PubMed ID: 26948423
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus latent membrane protein 1 modulates distinctive NF- kappaB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression.
Kung CP; Raab-Traub N
J Virol; 2010 Jul; 84(13):6605-14. PubMed ID: 20410275
[TBL] [Abstract][Full Text] [Related]
5. Roles of TRAF2 and TRAF3 in Epstein-Barr virus latent membrane protein 1-induced alternative NF-kappaB activation.
Song YJ; Kang MS
Virus Genes; 2010 Oct; 41(2):174-80. PubMed ID: 20585848
[TBL] [Abstract][Full Text] [Related]
6. Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-κB noncanonical and canonical pathway activation.
Farhana L; Dawson MI; Murshed F; Fontana JA
Cell Death Differ; 2011 Jan; 18(1):164-73. PubMed ID: 20671747
[TBL] [Abstract][Full Text] [Related]
7. The noncanonical NF-κB pathway.
Sun SC
Immunol Rev; 2012 Mar; 246(1):125-40. PubMed ID: 22435551
[TBL] [Abstract][Full Text] [Related]
8. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency.
He JQ; Zarnegar B; Oganesyan G; Saha SK; Yamazaki S; Doyle SE; Dempsey PW; Cheng G
J Exp Med; 2006 Oct; 203(11):2413-8. PubMed ID: 17015635
[TBL] [Abstract][Full Text] [Related]
9. Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival.
Yang CH; Murti A; Pfeffer LM
J Biol Chem; 2005 Sep; 280(36):31530-6. PubMed ID: 16009713
[TBL] [Abstract][Full Text] [Related]
10. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.
Demchenko YN; Glebov OK; Zingone A; Keats JJ; Bergsagel PL; Kuehl WM
Blood; 2010 Apr; 115(17):3541-52. PubMed ID: 20053756
[TBL] [Abstract][Full Text] [Related]
11. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation.
Razani B; Zarnegar B; Ytterberg AJ; Shiba T; Dempsey PW; Ware CF; Loo JA; Cheng G
Sci Signal; 2010 May; 3(123):ra41. PubMed ID: 20501937
[TBL] [Abstract][Full Text] [Related]
12. Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling.
Takaori-Kondo A; Hori T; Fukunaga K; Morita R; Kawamata S; Uchiyama T
Biochem Biophys Res Commun; 2000 Jun; 272(3):856-63. PubMed ID: 10860842
[TBL] [Abstract][Full Text] [Related]
13. TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor.
Bista P; Zeng W; Ryan S; Bailly V; Browning JL; Lukashev ME
J Biol Chem; 2010 Apr; 285(17):12971-8. PubMed ID: 20185819
[TBL] [Abstract][Full Text] [Related]
14. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.
de Oliveira KA; Kaergel E; Heinig M; Fontaine JF; Patone G; Muro EM; Mathas S; Hummel M; Andrade-Navarro MA; Hübner N; Scheidereit C
Genome Med; 2016 Mar; 8(1):28. PubMed ID: 26988706
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation.
Liao G; Zhang M; Harhaj EW; Sun SC
J Biol Chem; 2004 Jun; 279(25):26243-50. PubMed ID: 15084608
[TBL] [Abstract][Full Text] [Related]
16. Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways.
Müller JR; Siebenlist U
J Biol Chem; 2003 Apr; 278(14):12006-12. PubMed ID: 12556537
[TBL] [Abstract][Full Text] [Related]
17. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs.
Hauer J; Püschner S; Ramakrishnan P; Simon U; Bongers M; Federle C; Engelmann H
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2874-9. PubMed ID: 15708970
[TBL] [Abstract][Full Text] [Related]
18. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
[TBL] [Abstract][Full Text] [Related]
19. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation.
Saitoh T; Nakayama M; Nakano H; Yagita H; Yamamoto N; Yamaoka S
J Biol Chem; 2003 Sep; 278(38):36005-12. PubMed ID: 12840022
[TBL] [Abstract][Full Text] [Related]
20. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
